Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • A Phase 1/2, Open-Label, Dose Escalation and Cohort Expansion Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARV-110 in Patients with Metastatic Castration-Resistant Prostate Cancer

    Cancer Categories
    • Genitourinary (GU)
    Karmanos Trial ID
    • 2020-055
    NCT ID
    • NCT03888612
    Age Group
    • Adult
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I/II
    Principal Investigator


    Primary Objective:
    • To evaluate the safety and tolerability of ARV110 in successive cohorts of patients with prostate cancer in order to estimate the maximum tolerated dose or maximum administered dose and select the recommended Phase 2 dose/schedule.
    Secondary Objectives:
    • To characterize the single and multiple-dose of ARV110 and its enantiomers ARCC51A and ARCC51B.
    • To explore the preliminary anti-tumor activity in the entire study population and relevant molecularly defined subsets of patients.
  • Locations


    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266